HIV

News

ViiV’s Rukobia cleared in EU as rescue HIV therapy

The European Commission has given a green light to the use of ViiV Healthcare’s Rukobia as a treatment for people with HIV that has developed resistance to other antiretroviral therapy (ART

News

ViiV/J&J's long-acting HIV regimen finally approved in US

The FDA has approved Cabenuva, a long-acting HIV treatment from ViiV and Johnson & Johnson that keeps the virus at bay with a monthly injection instead of daily pill regimen.

News

ViiV launches digital triage service for HIV patients with L...

ViiV Healthcare and London’s Westminster Hospital NHS Foundation Trust have launched a digital triage service for HIV patients supported by a mobile app.

News

Tivicay approved in Europe in new dispersible tablet for chi...

ViiV’s Tivicay is to become available in Europe in a new dispersible tablet form to treat children living with HIV.

News

Data sets up 2021 filings for Gilead's twice-a-year HIV drug...

Gilead Sciences has the data it was hoping for in a pivotal trial of lenacapavir, an HIV drug that only needs to be dosed by subcutaneous injection every six months, keeping it on course fo

News

ViiV could challenge Gilead with long-acting HIV PrEP shot

GlaxoSmithKline’s HIV joint venture ViiV Healthcare could mount a challenge to Gilead’s HIV pre-exposure prophylaxis (PrEP) medicines after the FDA granted Breakthrough Therapy Designation

ViiV’s Rukobia cleared in EU as rescue HIV therapy

ViiV/J&J's long-acting HIV regimen finally approved in US

ViiV launches digital triage service for HIV patients with L...

Tivicay approved in Europe in new dispersible tablet for chi...

Data sets up 2021 filings for Gilead's twice-a-year HIV drug...

ViiV could challenge Gilead with long-acting HIV PrEP shot

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

HIV

Editor's Picks